Kyverna Therapeutics, Inc. Common Stock (KYTX)
Healthcare
Biotechnology
7.50 $
+2.9%
vs. previous close
Closing price · As of: 3. Aug 2026
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Kyverna Therapeutics, Inc. Common Stock (KYTX) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 07/29/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document → |
| 07/27/2026 | Current report (8-K) | Kyverna Therapeutics, Inc. (KYTX): Entry into a Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibits | View report → |
| 07/09/2026 | Current report (8-K) | Kyverna Therapeutics, Inc. (KYTX): Entry into a Material Definitive Agreement; Financial Statements and Exhibits | View report → |
Showing the 100 most recent filings of the selected type.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.